Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
AbbVie, advice, Afrin, Agencia, agile, Akorn, alendronate, allergen, Allergenic, Alnylam, Amgen, amnestic, anniversary, API, aprepitant, Aquaflor, Arcoxia, Aspen, ASR, auction, Avelox, Banamine, Bank, Bedford, Ben, benzoate, bid, biosimilar, BMS, bolstering, bound, Brazilian, breadth, breakthrough, broadly, Byetta, Canan, capable, Caravello, Cerazette, Chilcott, Chinese, Clarinex, Claritin, Clostridium, Coccivac, cognitive, colorectal, Compact, Complimentary, concomitant, confident, confirmatory, Coppertone, Coricidin, cotransporter, coupled, creation, CRL, desloratadine, desogestrel, developmental, devoting, discrimination, discriminatory, disparate, Dulera, dust, ear, effectuate, EPO, ertapenem, ertugliflozin, Estrumate, etoricoxib, Eurofarma, Ezetrol, facilitate, Farma, Fast, fed, feed, fluroquinolone, follicular, follitropin, footprint, Forest, Fosamac, Fosavance, Francisco, Franklin, gastric, glargine, Glynn, Goldman, Grastek, HBP, HCl, HCV, heightened, hostile, house, Implanon, inconsistent, incorrect, Inegy, Interactive, intolerant, Invanz, ipilimumab, Jellema, Karachun, Kelli, kinase, Korea, lesser, Lotrimin, Love, lump, Marvelon, Maryland, mild, mobile, modality, Montana, moxifloxacin, multinational, Munter, Nacional, neck, Nobivac, nonproprietary, Nuflor, omarigliptin, Ono, Oxytrol, Paracox, parasiticide, perlmutter, philanthropic, platform, Pneumovax, policymaker, posaconazole, preempted, preemption, Primaxin, proactive, prodromal, proper, Proscar, Puregon, Ragwitek, Rebetol, recurrence, Remeron, repricing, Resflor, resignation, retaliation, retroactively, Revalor, revocation, revoke, Rita, rizatriptan, ROGER, Rosenberg, round, ruminant, salt, Samsung, San, Scheinberg, Sessner, sharpen, SICAD, Sirna, Slice, Spano, sponte, spun, St, staggered, sua, successor, sue, Supera, surrogate, suspension, Sweet, Sycrest, Taxpayer, Temodal, tildrakizumab, timeline, Timothy, Tinactin, toll, top, Track, triple, true, Trusopt, Unanski, unfiled, unrepatriated, vacate, vacated, valent, Varivax, verify, Victoza, Vigilancia, Warner, weekly, winding, Zegerid, Zilmax, Zocor, Zoely, Zuprevo
Removed:
air, alpha, anal, ANDA, andAquaflorantibiotic, andClarinex, andFosamax, andIntron, andPorcilisvaccine, andResearch, andVytorin, andZegerid, angiotensin, argument, ARIAD, asAeriusin, asEzetrol, asEzetroloutside, asFosamacin, asFosavancethroughout, asInegy, asInegyoutside, asNoncontrolling, asOther, asPuregon, assetsare, assetswere, atorvastatin, atrial, balancing, beende, body, butsua, captionIn, certainFosamaxproduct, cervical, commencing, commercializeSimponi, competitor, concerningVytorinand, Conservation, consolidatedIncome, constituted, consultation, conversion, convertible, Coppertonesun, CR, damage, diminution, disputed, dissolvable, downturn, dupont, dysplastic, enterprise, equipmentand, estrogen, factual, fibrillation, forCosoptwill, forMaxalt, forMaxaltwill, forSimponi, forSingulair, FosamaxLitigation, Frameworkissued, Fred, fromAOCI, gastrointestinal, genital, glaucoma, Glenmark, Greek, groundwater, halted, Hamni, Hassan, HDL, heard, hemorrhage, Impax, inAccrued, inAccumulated, inAOCIand, incidence, includeCozaarandHyzaar, incomein, inDeferred, India, inducing, inEquity, informed, inInternal, inNoncontrolling, inOCI, inOther, inProperty, inRestructuring, inRosenberg, interestsin, intoSaleswhen, intracranial, intraocular, isde, JanuviaandJanumetfor, KIM, laropiprant, liabilitieswere, licensor, mammalian, marketCozaarandHyzaar, men, metastatic, Mexico, minimisand, mTOR, municipal, nameSycrest, naturally, negligence, niacin, Nuflorantibiotic, nuisance, NuvaRingMDL, ocular, ofAccumulated, ofBridionwere, ofCozaar, ofCozaarand, ofEmend, ofFollistim, ofFosamax, ofFosamaxand, ofFosamaxandFosamax, ofGardasil, ofJanumet, ofJanuvia, ofMaxalt, ofNasonex, ofNuvaRing, ofOCI, ofOther, ofPneumovax, ofPrimaxin, ofPropecia, ofSimponi, ofSingulair, ofSingulairin, ofTemodar, ofVioxx, ofVytorin, ofVytorinandZetia, ofVytorinandZetiain, ofZetia, onPrimaxinhave, onVioxxby, page, parent, participated, peripheral, phased, productsper, prostaglandin, purportedly, rapamycin, receivableandAccrued, reducedIncome, regained, remeasure, retiree, retirement, revascularization, sarcoma, secondary, selective, Sliceparasiticide, soil, sponsored, sponteordered, Standardsapplicable, subsidy, sugar, surgical, tafluprost, taxesby, taxeswould, TheBolescase, theFosamaxproduct, theNuvaRing, theNuvaRingMDL, thevioxx, thevioxxlitigation, thevioxxproduct, theVytorin, thrombin, throughOther, toAggrastat, toOther, toSalesmay, toSimponi, toVioxx, toVioxxin, toVytorin, TRACER, treating, unamortized, updated, vernakalant, virtue, vulvar, withdraw, withdrewVioxx, withinOCI, withinRestructuring, working, write, XR
Filing tables
Filing exhibits
- 10-K Annual report
- 3.2 EX-3.2: By-laws of Merck & Co., Inc. (Eff Feb 25 2014)
- 12 EX-12: Computation of Ratio of Earnings to Fixed Charges
- 21 Ex 21: Subsidiaries
- 23 EX-23: Consent of Independent Registered Public Accounting Firm
- 24.1 EX-24.1: Power of Attorney
- 24.2 EX-24.2: Certification of Board Resolution
- 31.1 EX-31.1: CEO Certification
- 31.2 EX-31.2: CFO Certification
- 32.1 EX-32.1: CEO Certification
- 32.2 EX-32.2: CFO Certification
- Download Excel data file
- View Excel data file
Related press release
MRK similar filings
Filing view
External links
Exhibit 23
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-185248, 333-185245, 333-164482, 333-163858 and 333-163546) and on Form S-8 (Nos. 333-173025, 333-173024, 333‑162882, 333-162883, 333-162884, 333-162885, 333-162886, 333-134281, 333-121089 and 333-91440) of Merck & Co., Inc. of our report dated February 27, 2014 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
PricewaterhouseCoopers LLP
Florham Park, New Jersey
February 27, 2014